Physician profile
David Lipschitz
NPI 1225006513
$11,360.88
in general payments reported to CMS, 2019-2025
39 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,421 · 2020: $637 · 2021: $1,520 · 2022: $1,537 · 2023: $1,487 · 2024: $1,869 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,234 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,234.11 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,582.40 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $1,293.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,230.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,199.40 | 2019-2025 | |
| Abbvie INC. | $843.35 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $651.59 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $597.37 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $424.78 | 2019-2025 | Eliquis |
| Dexcom, INC. | $367.45 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $334.20 | 2019-2024 | Verquvo, Belsomra, Gardasil |
| Amgen INC. | $310.11 | 2019-2025 | Evenity, Prolia, Repatha |
| Biohaven Pharmaceutical Holding Company Ltd. | $244.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $239.01 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $235.15 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $215.58 | 2019-2022 | Tlando, Xyosted |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $164.14 | 2024 | Urolift |
| Astellas Pharma US INC | $143.29 | 2019-2023 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $138.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $129.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.57 | 2019-2025 | Xifaxan |
| Intuitive Surgical, INC. | $119.36 | 2025 | |
| Boston Scientific Corporation | $93.45 | 2020 | |
| Lilly USA, LLC | $89.77 | 2019-2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $77.94 | 2019-2023 | Injectafer |
| Pacira Pharmaceuticals Incorporated | $73.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $68.45 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $56.37 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $54.82 | 2019 | |
| Abbott Laboratories | $45.27 | 2025 | Freestyle Libre 3 |
| Allergan, INC. | $33.66 | 2019 | |
| Grt US Holding, INC. | $31.01 | 2021-2022 | |
| Horizon Therapeutics Plc | $29.05 | 2022 | |
| Sunovion Pharmaceuticals INC. | $22.45 | 2022 | |
| Halozyme INC | $21.92 | 2023 | |
| Tolmar, INC. | $19.85 | 2025 | Jatenzo |
| Esperion Therapeutics, INC. | $17.86 | 2021 | |
| Inari Medical, INC. | $14.79 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shield Therapeutics INC | $14.31 | 2025 | |
| Amarin Pharma, INC. | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lipschitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.